US 11,931,333 B1
Topical treatment of herpes infections
Peter Van Horn, Salt Lake City, UT (US); and John M. Guynn, Salt Lake City, UT (US)
Filed by Peter Van Horn, Salt Lake City, UT (US); and John M. Guynn, Salt Lake City, UT (US)
Filed on May 28, 2020, as Appl. No. 16/886,730.
Claims priority of provisional application 62/853,712, filed on May 28, 2019.
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 31/05 (2006.01); A61K 31/522 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/44 (2017.01); A61P 31/22 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 31/05 (2013.01); A61K 31/522 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/44 (2013.01); A61P 31/22 (2018.01); A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01)] 19 Claims
 
1. A method of treating a herpes infection comprising topically applying a topical treatment composition to a treatment site of a person in need thereof, the topical treatment composition comprising:
a liquid carrier comprising dimethyl sulfoxide (DMSO) and a diluent; and
an anti-viral agent comprising at least one water soluble quaternary ammonium compound included at a concentration so that, when applied to the treatment site together with the DMSO, treats the herpes infection by providing anti-viral activity at the treatment site,
wherein the liquid carrier comprises 50-70% DMSO and 50-30% diluent and the at least one water soluble quaternary ammonium compound comprises benzalkonium chloride.